

יולי 2024

## סילבוס בחינה בקרדיולוגיה 2024

1. ספר הלימוד של בראונזוואלד מהדורה 12 (יצא לאור ב- 2021)

2. קווי ההנחיה המעודכנים של ה-ESC עד ל-1.9.2024 (כולל קווי ההנחיה שיפורסמו במהלך כנס ה-ESC 2024). אלה כוללים:

**Atrial Fibrillation**  
**Chronic Coronary Syndromes**  
**Peripheral artery disease**  
**Elevated blood pressure and hypertension**

3. מאמרים מרכזיים בקרדיולוגיה שפורסמו (Hardcopy) בעיתונות להלן מה- 1.1.2021 ועד ל-1.6.2024 (ראו רשימת מאמרים מלאה מטה):

New England Journal of Medicine

Lancet

JAMA

Circulation

Journal of the American College of Cardiology

European Heart Journal

4. מסמכי עמדה של האיגוד הקרדיולוגי בישראל מה 1.1.2020 ועד ה- 1.6.2024 והערות האיגוד למסמכי העמדה של ה-ESC.

בהצלחה!

## **רשימת מאמרים לבחינת ההתמחות בקרדיולוגיה 16-17/12/2024**

**Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation. TOMAHAWK Investigators;** N Engl J Med. 2021 Dec 30;385(27):2544-2553.

**Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. MASTER DAPT Investigators;** N Engl J Med. 2021 Oct 28;385(18):1643-1655.

**Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. REVIVED-BICIS2 Investigators;** N Engl J Med. 2022 Oct 13;387(15):1351-1360.

**Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI; FLAVOUR Investigators;** N Engl J Med 2022;387:779-789

**Transcatheter repair for patients with tricuspid regurgitation: TRILUMINATE;** NEJM 2023 May 18; 388:1833-1842

**Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years; PARTNER 3 Investigators;** N Engl J Med 2023; 389:1949-1960

**Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation; COAPT Investigators;** N Engl J Med 2023;388:2037-2048

**Once-Weekly Semaglutide in Adults with Overweight or Obesity;** Published February 10, 2021 N Engl J Med 2021;384:989-1002

**SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe**

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration Author Notes; European Heart Journal, Volume 44, Issue 28, 21 July 2023, Pages 2544–2556,

**Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk Authors: the PROMINENT Investigators\*** Published November 5, 2022 N Engl J Med 2022;387:1923-1934 VOL. 387 NO. 21

**Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189.**

**Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. N Engl J Med. 2021 Jul 15;385(3):203-216. doi: 10.1056/NEJMoa2026141. Epub 2021 May 16. PMID: 33999544; PMCID: PMC8353658.**

**ADVOR Study Group. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27. PMID: 36027559.**

**Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. PMID: 36027570.**

**The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. PMID: 35228754; PMCID: PMC8938265.**

**Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7. PMID: 36356631.**

**Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. PMID: 33200892.**

**Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 May 30;390(20):1849-1861. doi: 10.1056/NEJMoa2401424. Epub 2024 May 13. PMID: 38739079.**

**Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25. PMID: 37622681.**

**Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26. PMID: 37632463.**

**Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.** N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757. PMID: 37888916; PMCID: PMC10757426.

**Timing of complete revascularization with multivessel PCI for myocardial infarction.** N Engl J Med 2023;389:1368–79. <https://doi.org/10.1056/NEJMoa2307823>

**Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study.** Circulation 2023;147:108–17. <https://doi.org/10.1161/CIRCULATIONAHA.122.062770>

**Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.** N Engl J Med. 2024 Apr 18;390(15):1372-1381. doi: 10.1056/NEJMoa2401479. Epub 2024 Apr 7. PMID: 38587241.

**Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.** N Engl J Med. 2023 Oct 5;389(14):1286-1297. doi: 10.1056/NEJMoa2307227. Epub 2023 Aug 26. PMID: 37634145.

**Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.** N Engl J Med. 2024 Apr 18;390(15):1382-1393. doi: 10.1056/NEJMoa2312572. Epub 2024 Apr 7. PMID: 38587239.

**Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.** N Engl J Med. 2021 Aug 5;385(6):516-525. doi: 10.1056/NEJMoa2026845. PMID: 34347952.

**Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.** Lancet. 2024 Jun 15;403(10444):2606-2618.

**CT or Invasive Coronary Angiography in Stable Chest Pain.** DISCHARGE Trial Group; N Engl J Med. 2022 Apr 28;386(17):1591-1602

**Influence of Cardiac Remodeling on Clinical Outcomes in Patients With Aortic Regurgitation.** J Am Coll Cardiol. 2023 May 16;81(19):1885-1898.

**Fate of the unoperated ascending thoracic aortic aneurysm: three-decade experience from the Aortic Institute at Yale University.** Eur Heart J. 2023 Nov 14;44(43):4579-4588. doi: 10.1093/eurheartj/ehad148. PMID: 36994934.

**PREVENT Investigators. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.**

Lancet. 2024 May 4;403(10438):1753-1765.

**Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.** N Engl J Med. 2023 Nov 2;389(18):1660-1671.

**ARTESIA Investigators. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.** N Engl J Med. 2024 Jan 11;390(2):107-117

**CASTLE HTx Investigators. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation.** N Engl J Med. 2023 Oct 12;389(15):1380-1389.

**Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.** Circulation. 2023 Mar 7;147(10):812-823

**Asymptomatic Patients with Brugada ECG Pattern: Long-Term Prognosis From a Large Prospective Study.** Circulation. 2023 Nov 14;148(20):1543-1555